Early antiviral treatment reduced the risk of organ rejection and heart complications by nearly half for up to one year after diagnosis.
RT’s Three Key Takeaways:
- Reduced Graft Loss: Early treatment with remdesivir was associated with a 47% lower risk of all-cause graft loss in adult kidney transplant recipients compared to those who did not receive the antiviral.
- Cardiovascular Protection: Patients receiving at least three days of remdesivir therapy within a week of diagnosis saw a 42% reduction in the risk of cardiovascular complications, such as heart attack or stroke.
- Long-Term Benefits: The findings suggest that timely antiviral intervention provides protective benefits that extend well beyond the acute phase of COVID-19, potentially reducing systemic inflammation and vessel damage.
Adult kidney transplant recipients who received the antiviral remdesivir within seven days of a COVID-19 diagnosis were significantly less likely to suffer from cardiovascular or kidney issues a year later, according to a study published in JAMA Network Open.
The target trial emulation study found that patients who received at least three consecutive days of therapy experienced better outcomes than those who did not receive the antiviral. Investigators from Johns Hopkins Medicine identified 432 adult kidney transplant recipients diagnosed with COVID-19 between March 2020 and January 2024 to assess long-term health impacts.
“These findings suggest that timely antiviral treatment may have benefits beyond the acute phase of COVID-19 in this population,” said Nitipong Permpalung, MD, MPH, senior study author and associate director of the Johns Hopkins Transplant Research Center, in a news release. “We hope these findings will help reduce hesitations that physicians may have with considering providing remdesivir, when clinically appropriate, to adult kidney transplant recipients.”
Study Results and Respiratory Impact
The study population included many patients with underlying risk factors for severe COVID-19. At the time of diagnosis, 88 adults (20%) required supplemental oxygen. Among the participants, 177 received remdesivir intravenously, while 255 did not. Patients in the remdesivir group were generally older and more likely to require breathing assistance, with 33% needing respiratory support compared to 11% in the non-remdesivir group.
After adjusting for variables such as age, vaccination status, and disease severity, the research team determined that early remdesivir treatment was associated with a 47% lower risk of all-cause graft loss. This was defined as either death from any cause or the rejection of the kidney transplant. Additionally, the treated group saw a 42% lower risk of cardiovascular events, including stroke and heart attack.
Physicians managing these cases must often balance immune function, kidney health, and the use of immune-suppressing therapies. According to the study, 59% of participants stopped taking immunosuppressive drugs at the time of their COVID-19 diagnosis to help fight the infection.
Biological Mechanisms
The researchers suggested that the antiviral’s ability to stop the virus from spreading early in the infection may prevent cascading health issues.
“Several biologically plausible mechanisms may explain the observed associations,” said Karan Srisurapanont, MD, the first study author, in a news release. “Early suppression of viral replication may reduce systemic inflammation, endothelial injury, or damage to blood vessels, and thrombotic complications, or those related to severe blood clotting, that may contribute to heart and kidney problems.”
While the study showed clear associations regarding graft survival and heart health, the results for long COVID were inconclusive due to the small number of documented cases in the study group. The investigators noted that kidney transplant recipients are often excluded from randomized trials due to their complex underlying risks, making this data particularly valuable for healthcare providers managing high-risk respiratory infections in transplant populations.
